Navigation Links
Study Presented at the ACC Shows Inflammatory Enzyme Lp-PLA2,Predicts Heart Disease Risk in Metabolic Syndrome Patients

NEW ORLEANS--(BUSINESS WIRE)--Mar 26, 2007 - Study results show that elevated lipoprotein-associated phospholipase A2 (Lp-PLA2), a cardiovascular-specific inflammatory enzyme associated with unstable plaque that can lead to heart attack and stroke, is especially predictive of heart disease risk in patients with the metabolic syndrome--a serious medical condition that affects nearly 50 million Americans. The results, which were presented yesterday at the American College of Cardiology's annual scientific session, confirm previous findings demonstrating the association between elevated Lp-PLA2 and coronary heart disease.

Investigators at the University of Utah in Salt Lake City used the PLAC test from diaDexus to measure Lp-PLA2 levels in blood samples from almost 1,500 patients enrolled in the Intermountain Heart Collaborative Study. The patients also underwent coronary angiography to determine the presence of heart disease and were tracked for up to 10 years. Results showed that Lp-PLA2 was a clinically important predictor of heart disease and future death in patients with the metabolic syndrome, a dangerous precursor to diabetes characterized by high blood pressure, high triglycerides, high fasting blood glucose, low high-density lipoprotein, and small, dense low-density lipoprotein. Lp-PLA2 also predicted heart disease death risk in non-metabolic syndrome patients.

According to Richard Lanman, M.D., diaDexus' chief medical officer, the findings are important because of the large number of patients with the metabolic syndrome who may be at significantly increased risk for diabetes, stroke, and heart disease. "Interest in the metabolic syndrome has been increasing along with Americans' growing waistlines," Lanman said. "This study confirms earlier results indicating that elevated Lp-PLA2 is independent from and additive to the increased cardiovascular risk associated with insulin resistance. The addition
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:5/22/2013)... 22, 2013  MGT Capital Investments, Inc. (NYSE MKT: ... the Second Annual Marcum LLP MicroCap Conference on Thursday, ... at the Grand Hyatt Hotel.  ... will update investors and answer questions. (Logo: ... is scheduled to begin at 9:30 a.m. EDT.  MGT,s ...
(Date:5/22/2013)... MANALAPAN, N.J. , May 22, 2013 ... this opportunity to update shareholders about some recent company ... will expand its avenues of communication with shareholders. Integrating ... has launched a Facebook page and will post updates ... the Twitter hashtag is #medifirstusa. Says ...
(Date:5/22/2013)... May 22, 2013  Avanir Pharmaceuticals, Inc. (NASDAQ: ... overview of the company at the following conferences. ... Presentation date: Wednesday May 29, 2013 , Presentation time: ... Healthcare Conference , Presentation date: Wednesday June 5, 2013 ... A live webcast and 30-day archive of ...
Breaking Medicine Technology:MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 3MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 4Medifirst Solutions, Inc. Announces Update To Shareholders 2Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences 2
... May 18, 2011 Oclaro, Inc. (NASDAQ: ... communications and laser solutions, today outlined its complete line ... of future products.  As a leading provider of diodes ... leverage its world-class manufacturing operations, technology expertise and packaging ...
... 18, 2011 Cempra Pharmaceuticals Inc. today announced that Prabhavathi ... two upcoming investor conferences in Paris.  Dr. Fernandes will present ... a.m. CET, May 24, at the Hilton Arc de Triomphe. ... at 3:00 p.m. CET, May 24, at the Paris ...
Cached Medicine Technology:Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements 2Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements 3Cempra Pharmaceuticals to Present at Two Investor Conferences in Paris 2
(Date:5/22/2013)... Los Angeles, CA (PRWEB) May 22, 2013 ... board, The J. M. Smucker Company, and Danny ... Awards yesterday at the GS1 General Assembly and Global ... Mr. Smucker and Mr. Wegman were recognized for their ... Standards - the most broadly used supply chain standards ...
(Date:5/22/2013)... report these findings in the current online edition ... pan-European study could open up new possibilities of ... which tackle diseases before the patient,s nervous system ... group of genetic diseases of the cerebellum and ... have limited control of their muscles. They also ...
(Date:5/22/2013)... new guidelines the first in more than 35 ... for surgical patients. The recommendations, based on a lengthy ... (JHH), can potentially save the medical center more than ... , A report on the research that led up ... Anesthesiology , suggests millions of dollars a year ...
(Date:5/22/2013)... Toppik and Bosley hair fibers, two hair loss concealer products ... hair. Hair loss treatments can be a lengthy process. In ... waiting period, one can use these hair loss concealers. They ... surgery in general. , Bosley and Toppik Hair Thickening ... eliminate the appearance of balding and thinning hair. It is ...
(Date:5/22/2013)... NC (PRWEB) May 22, 2013 The 2013 ... (DSM-5) is the largest change to hit the field ... Jung Center is will help prepare for the release with ... therapists has been trained knowing no other diagnostic scheme besides ... DSM-5 diagnostic manual will be released worldwide. In honor of ...
Breaking Medicine News(10 mins):Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 3Health News:A pan-European study: Signs of motor disorders can appear years before disease manifestation 2Health News:A pan-European study: Signs of motor disorders can appear years before disease manifestation 3Health News:Johns Hopkins rewrites obsolete blood-ordering rules 2Health News:Johns Hopkins rewrites obsolete blood-ordering rules 3Health News:TheBeautyPlace.com Divulges Two Innovative Hair Loss Concealers on the Market Today: Bosley Hair Thickening Fibers and Toppik Hair Building Fibers 2Health News:What You Need to Know About DSM-5: The Asheville Jung Center is Hosting a Webinar Tonight on the New Material in DSM-5 2
... Conferring with pharmacists permits quicker changes in drugs, improved ... -- Monitoring your blood pressure at home and reporting ... keep blood pressure readings lower than standard care does, ... half of people who used this system of blood ...
... AUSTIN, TexasMechanical engineering Assistant Professor Adela Ben-Yakar at The ... "microscalpel" that destroys a single cell while leaving nearby ... for cancer, epilepsy and other diseases. , "You can ... damaging the cells above and below it," Ben-Yakar says. ...
... Brava, LLC announces a major milestone.,Since its introduction 7 ... have used the Brava Breast Enhancement System. The Brava,system ... from,Brava in the United States and through international distributors ... V. Freyre, President and CEO of Brava, "We are ...
... Cycle Would Create a ,Stampede, of Other ... WASHINGTON, June 24 As policymakers ... package, they face the decision of,either supporting ... postponing the Average Manufacturer Price (AMP) pharmacy ...
... WASHINGTON, June 24 The American Lung,Association commends ... its,passage of the Pulmonary and Cardiac Rehabilitation Act ... Patients and Providers Act of,2008, the Pulmonary and ... make life easier for millions of Americans who ...
... who goes for tests, study concludes , , TUESDAY, ... from colorectal cancer among minorities in United States may ... cultural barriers that lead to less preventative screening among ... The report, published in the June 23 issue of ...
Cached Medicine News:Health News:Going Online to Draw the Line on High Blood Pressure 2Health News:Going Online to Draw the Line on High Blood Pressure 3Health News:Laser surgery probe targets individual cancer cells 2Health News:Time for Policymakers to Choose: 'Prompt Pay' Mandate or Postpone AMP Reimbursement Cuts 2Health News:American Lung Association Commends U.S. House of Representatives for Passage of Pulmonary and Cardiac Rehabilitation Act 2Health News:Social, Health Care Factors Drive Colon Screen Disparities 2
Angled shafts, smooth jaws, polished finish....
... insertion of second generation 6 millimeter foldable ... millimeters, and is perfect for clear corneal ... rounded blades provide a secure grip of ... controlled release of the optic through a ...
Autoref / Ker N vision K 5001 has auto fogging, wide view window, near vision reading. Clear 5.6 Inch color monitor. Data screen function. SE Value display function. Quick printer with automatic cutt...
... Auto-Kerato Refractometer combines an auto-refractor, an auto-keratometer, ... all in a single, compact unit. This ... the diagnostic capabilities in one-third the space, ... the individual instruments. By implementing Topcons exclusive ...
Medicine Products: